Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Arcutis Biotherapeutics Inc ARQT

Healthcare Biotechnology
Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company. The Company is focused on developing and commercializing treatments for dermatological diseases with high-unmet medical needs. Its portfolio is comprised of topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. Its lead product, ZORYVE, is for the treatment... see more

Current News (NDAQ:ARQT)

Arcutis Completes Enrollment in INTEGUMENT-INFANT Phase 2 Study Evaluating ZORYVE® (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis

GlobeNewswire 3 days ago

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire 8 days ago

Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data of ZORYVE® (roflumilast) Foam 0.3% in Individuals with Seborrheic Dermatitis in American Journal of Clinical Dermatology

GlobeNewswire 12 days ago

Mother-Daughter Duo, Tori Spelling and Stella McDermott, Partner With Arcutis Biotherapeutics in the Free to Be Me Campaign, Urging People With Inflammatory Skin Conditions to Speak With Their Healthcare Provider About Long-Term Treatments

GlobeNewswire October 30, 2025

Arcutis Launches ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Children Ages 2 to 5

GlobeNewswire October 30, 2025

Arcutis Outlines Strategy for Driving Sustainable Growth and Announces Third Quarter 2025 Financial Results

GlobeNewswire October 28, 2025

Arcutis to Present at Upcoming Investor Conferences

GlobeNewswire October 27, 2025

Arcutis to Present New Quality of Life and Long-Term Data with ZORYVE® (roflumilast) Cream 0.15% and 0.05% for the Treatment of Atopic Dermatitis at the Fall Clinical Dermatology Conference

GlobeNewswire October 24, 2025

FDA Approves Arcutis' ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5

GlobeNewswire October 6, 2025
View More News ››

Opinion & Analysis (NDAQ:ARQT)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:ARQT)

KEY CATALYSTS MAKE ARCUTIS A MUST WATCH!

$ARQT Excited to share our latest article on Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT), a biopharmaceutical company...
AviseAnalytics - July 25, 2022

5 PROMISING STOCKS IN ALOPECIA AREATA

5 PROMISING STOCKS IN ALOPECIA AREATA   1 In 5 Americans Are Losing Their Hair... More than 50 percent of women experience...
AviseAnalytics - July 7, 2021
View more Bullboard ››

Eshbal Functional Food Inc

Eshbal Functional Food Inc

Eshbal Functional Food Inc. is a Canada-based food-tech company. With over 300 SKUs, including 80+ proprietary Better for You ...
View More »